1st Quarter - Report

VIR BIOTECHNOLOGY, INC. for VIR BIOTECHNOLOGY, INC.

Firm
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 3799 PREVENT Pandemics Act; H.R. 2471 Consolidated Appropriations Act, COVID Supplemental Appropriations Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-9 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act.

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 2640 (117th), H.R. 2471 (117th), S. 3258 (117th), H.R. 6025 (117th), S. 3799 (117th)

Science/Technology SCI

Pandemic Preparedness

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Office of Science & Technology Policy (OSTP); SENATE; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Reimbursement of COVID-19 Therapeutics

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.